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Abstract
Background
Age-related macular degeneration (AMD) is a common disease causing visual impairment
and blindness. Various gene variants are strongly associated with late stage AMD, but little
is known about the genetics of early forms of the disease. This study evaluated associations
of genetic factors and different AMD stages depending on unilateral and bilateral disease
severity.
Methods
In this case-control study, participants were assigned to nine AMD severity stages based on
the characteristics of each eye. 18 single nucleotide polymorphisms (SNPs) were geno-
typed and attempted to correlate with AMD severity stages by uni- and multivariate logistic
regression analyses and trend analyses. Area under the receiver operating characteristic
curves (AUC) were calculated.
Results
Of 3444 individuals 1673 were controls, 379 had early AMD, 333 had intermediate AMD
and 989 showed late AMD stages. With increasing severity of disease and bilateralism
more SNPs with significant associations were found. Odds ratios, especially for the main
risk polymorphisms inARMS2 (rs10490924) andCFH (rs1061170), gained with increasing
disease severity and bilateralism (exemplarily: rs1061170: unilateral early AMD: OR = 1.18;
bilateral early AMD: OR = 1.20; unilateral intermediate AMD: OR = 1.28; bilateral intermediate
AMD: OR = 1.39, unilateral geographic atrophy (GA): OR = 1.50; bilateral GA: OR = 1.71).
Trend analyses showed p<0.0001 for ARMS2 (rs10490924) and forCFH (rs1061170),
respectively. AUC of risk models for various AMD severity stages was lowest for unilateral
early AMD (AUC = 0.629) and showed higher values in more severely and bilaterally affected
individuals being highest for late AMDwith GA in one eye and neovascular AMD in the other
eye (AUC = 0.957).
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Conclusion
The association of known genetic risk factors with AMD became stronger with increasing
disease severity, which also led to an increasing discriminative ability of AMD cases and
controls. Genetic predisposition was also associated with the disease severity of the fellow-
eye, highlighting the importance of both eyes in AMD patients.
Introduction
In age-related macular degeneration (AMD), heritability plays a major role in disease develop-
ment [1]. Several risk loci have been identified, but two loci are responsible for approximately
50% of the genetic risk: complement factor H (CFH) on chromosome 1q32 and age-related
maculopathy susceptibility 2 (ARMS2)/HtrA serine peptidase 1 (HTRA1) on chromosome
10q26 [2].
In AMD, the phenotype of the early stages is characterized by drusen and pigmentary
abnormalities. They usually cause little or no visual symptoms, but they are risk factors for pro-
gression to advanced AMD [3,4]. The advanced forms of AMD, namely geographic atrophy
(GA) and choroidal neovascularisation (CNV), are the leading causes of visual impairment
and blindness among the elderly [5]. These findings argue for the concept of a disease contin-
uum starting with few alterations, progressing into an intermediate stage with large drusen,
and finally resulting in the late-stage forms GA or neovascular AMD (nAMD). However, there
are a lot of patients who develop nAMD with only few early signs of the disease.
The identification of associated genetic variants can help to detect mechanisms of this com-
plex and heterogeneous condition. However, the majority of genetic studies were conducted
with late-AMD cases [6]. Few studies included early forms of the disease or investigated pro-
gression factors [7–10]. Therefore, little is known about the role of genetic variants in early
AMD or genetic factors driving the progression from early to late AMD. Twin studies indicated
a lower heritability for early AMD of only about 35–53% [9]. This is significantly lower than
the heritability for late AMD of up to 71% [11]. In a meta-analysis, only the two major risk
genes CFH and ARMS2/HTRA1 were associated with early AMD and the effect sizes were sig-
nificantly lower than for late AMD [10]. However, the reason for these findings is not known.
There are several possible explanations. There might be a clinical heterogeneity within the phe-
notype “early AMD” and some forms might be caused by other genetic factors. It is also possi-
ble that not all patients with signs of early AMD will progress to late stages because their retinal
changes result from other factors. Another explanation could be different individual effect sizes
for early and late AMD [12].
Hypothesizing, that there is not only a phenotypic, but also a genotypic disease continuum,
we analyze the associations of 18 single nucleotide polymorphisms (SNPs) in individuals show-
ing different AMD stages compared to controls. We also want to evaluate if genetic risk factors
vary for different phenotypes. In this case-control study, we additionally want to determine the
discrimination ability of genetic factors for unilateral and bilateral stages of early, intermediate,
and late AMD.
Methods
In our study, all participants with gradable images and available genetic analysis of the Euro-
pean Genetic Database (EUGENDA, www.eugenda.org) were included. EUGENDA is a large
case-control database for AMD with participants from the areas around Cologne in Germany
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and Nijmegen in the Netherlands. Study participants were unrelated, self-described Cauca-
sians, and at least 50 years of age. Controls were allowed to have other eye disease that did not
restrict AMD grading. The study was performed in accordance with the tenets of the Declara-
tion of Helsinki and the Medical Research Involving Human Subjects Act (WMO) and was
approved by the local ethics committee of the University Hospitals in Cologne and Nijmegen.
Written informed consent was obtained from all participants.
Grading
AMD staging was performed by certified graders (TS and LE) according to the standard protocol
of the Cologne Image Reading Center (CIRCL). Graders were blinded to the aims of this study.
Grading of retinal images included stereo fundus photographs, fluorescein angiograms and
SDOCTs. Controls were allowed to have only small drusen or pigmentary abnormalities with not
more than 9 small drusen in the Early Treatment of Diabetic Retinopathy Study (ETDRS) grid.
Control cases were additionally graded for changes of the outer retina in the whole SDOCT 6mm
x 4mm volume scans (Spectralis SDOCT, Heidelberg Engineering, Heidelberg, Germany, per-
formed by TS and EV). Eyes were termed as supercontrols, when both eyes showed an intact exter-
nal limiting membrane, ellipsoid zone and retinal pigment epithelium (RPE)-Bruch´s complex.
Early AMD was classified by the presence of at least 10 small drusen (<63 μm) and pigmen-
tary changes or the presence of 1–14 intermediate (63–124 μm) drusen in the ETDRS grid.
Intermediate AMD was classified by the presence of15 intermediate drusen or any large dru-
sen (125 μm in diameter). Advanced AMD with geographic atrophy (GA) was defined as
AMD with subfoveal atrophy of the RPE of at least 175μm diameter. Neovascular AMD
(nAMD) was characterized by choroidal neovascularization (CNV) secondary to AMD. AMD
staging was performed for both eyes separately and individuals were categorized in supercon-
trols, no AMD, unilateral early AMD, bilateral early AMD, unilateral intermediate AMD, bilat-
eral intermediate AMD, unilateral GA, bilateral GA, unilateral nAMD, bilateral nAMD, late
AMDmixed type. Late AMDmixed type was defined as CNV in one eye and GA in the other
eye. In cases termed “unilateral”, the grading differed between both eyes. The classification was
then based on the eye with the more severe AMD grading. (e.g. unilateral intermediate AMD
could have no AMD or early AMD in the fellow-eye). In late AMD, no ranking of severity
between GA and nAMD was made.
Genotyping
Genomic DNA was extracted from peripheral blood samples using standard procedures. Eigh-
teen SNPs in or near 13 AMD associated risk genes were chosen representing the major loci
associated with AMD which are CFH, ADAMTS9-AS2, COL8A1, CFI, C9, C2-CFB-SKIV2L,
VEGFA, TNFRSF10A, TGFBR1, ARMS2-HTRA1, B3GALTL, RAD51B, LIPC, CETP, C3,
APOE, SYN3-TIMP3, SLC16A8, COL4A3, PRLR-SPEF2, PILRB-PILRA, KMT2E-SRPK2,
TRPM3,MIR6130-RORB, ABCA1, ARHGAP21, RDH5-CD63, ACAD10, CTRB2-CTRB1,
TMEM97-VTN, NPLOC4-TSPAN10, CNN2,MMP9, C20orf85. [13]. Genotyping of SNPs in
the ARMS2 (rs10490924), CFH (rs1061170, rs800292, rs12144939), CFI (rs10033900), C3
(rs2230199, rs1047286), CFB (rs4151667, rs641153), TIMP3 (rs9621532), APOE (rs2075650,
rs4420638), CETP (rs3764261), VEGFA (rs943080), TGFBR1 (rs334353), SKIV2L (rs429698),
RAD51B (rs8017304) and TNFRSF10A (rs1327806) genes were carried out as previously
described [14]. With an allele-specific PCR, a fluorescent signal is generated through the use of
universal labeled primers, which can be quantified directly from microplates using standard
plate readers. The assay is conducted in closed-tube format to reduce the potential for contami-
nation to a minimum [14].
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Statistical analysis
Calculations were performed using SPSS software version 21.0 (IBM Software and Systems,
Armonk, NY, USA). Associations between AMD severity stages and SNPs were calculated by
univariate logistic regression analyses. For analysis, SNPs were categorized into “wild type”, the
“heterozygous” risk variant, and the “homozygous” risk variant. All analyses were adjusted for
age. Associations of other known risk factors (gender, smoking status, arterial hypertension
and diabetes) were tested using Chi2-test, age was tested using an analysis of variance
(ANOVA). Armitage’s trend test between the severity stages no AMD, unilateral early AMD,
bilateral early AMD, unilateral intermediate AMD, bilateral intermediate AMD, unilateral late
AMD and bilateral late AMD for each SNP (wild type / heterozygous vs. homozygous and wild
type vs. heterozygous / homozygous) was performed using SAS software version 9.3. Power
analysis was calculated with nQuery Advisor 7.0.
Odds ratios (OR) and 95% confidence intervals (CI) were calculated. P-values are two-sided
and were analyzed with the Chi2-test. P-values<0.05 were considered statistically significant.
For each severity stage, multivariate regression models were computed including all SNPs and
age of participants. Variables were not categorized for better visualization and comparability of
the results. The area under the receiver operating characteristic curve (AUC) was calculated to
check the genetic discriminative ability between cases of different AMD stages and healthy
controls.
Patients with unilateral nAMD were analyzed for associations with rs10490924 in ARMS2
and rs1061170 in CFH by univariate regression analysis and models were calculated by multi-
variate regression including both SNPs and age. Patients were differentiated based on disease
severity in the second eye with “no AMD”, “early AMD”, and “intermediate AMD”. Addition-
ally, Armitage’s trend test was performed for these severity stages of the fellow eye and both
SNPs.
Results
In the analysis, we included 3444 participants. Demographics and grading results are shown in
Table 1 and Table 2. For power calculation, Chi2-test was used comparing the patients with no
AMD (n = 1673) to any other group (type I error = 5%). We would be able to detect odds ratios
(e.g. wild type and heterozygous vs. homozygous) of 1.5 or greater with a power of 80% if the
sample size in the other group reached at least n = 218.
Distribution of SNPs and results of the trend analyses are summarized in Table 3 for
rs10490924 in ARMS2 and rs1061170 in CFH. Results of additional SNPs are presented in
S1 Table.
Univariate regression analysis of SNPs
Univariate regression analysis of SNPs was performed for all AMD severity stages. Detailed
results are outlined for main risk SNPs in ARMS2 and CFH in Table 4 and for additional SNPs
in S2 Table. Supercontrols showed no significant associations compared to subjects with no
AMD. However, ARMS2 and CFH rs1061170 showed lower OR in supercontrols but mostly
without reaching significance. In general, with increasing severity and bilateralism more SNPs
were associated with the disease and higher odds ratios were found.
Multivariate regression model for each severity stage
In the multivariate regression model, all 18 SNPs were included and age was used as a covari-
ate. Models were calculated for each AMD stage with “no AMD” as the reference variable.
Genetics of Unilateral and Bilateral Age-Related Macular Degeneration Severity Stages
PLOS ONE | DOI:10.1371/journal.pone.0156778 June 3, 2016 4 / 11
Increasing severity stages of AMD showed an almost continuous increase of odds ratios for
ARMS2 (rs10490924) and CFH (rs1061170) (Table 5). The influence of other SNPs was consid-
erably lower, rarely reaching significant p-values (S3 Table). The AUC showed increasing val-
ues with increasing AMD severity. Bilateral disease showed a higher AUC than unilateral
disease within each severity level. Highest genetic discrimination between controls and cases
(AUC = 0.957) was observed for late AMDmixed type. Details are shown in Table 6.
Severity levels of fellow-eyes in nAMD
Univariate regression analysis for rs10490924 in ARMS2 and rs1061170 in CFH was performed
for cases with nAMD in the study eye and different severity stages of the fellow-eye. With
increasing severity of the fellow-eye, increasing ORs were found (Table 7). A regression model
that included both SNPs revealed similar results (data not shown). The trend analysis showed
p = 0.009 (GG + GT vs. TT) and p = 0.001 (GG vs. GT + TT) for rs10490924 in ARMS2 and
p = 0.01 (TT + TC vs. CC) and p = 0.03 (TT vs. TC + CC) for rs1061170 in CFH, indicating
that the genetic associations increase with rising disease severity in the fellow-eye in unilateral
nAMD.
Table 1. Demographics.
No AMD Early AMD Intermediate AMD Late AMD p-value
Age (range) 69.0±7.9 (50–100) 72.1±8.0 (50–99) 73.8±9.0 (52–100) 76.9±8.3 (50–98) <0.001*
Female Sex 956/1673 (57.1%) 226/379 (59.6%) 209/333 (62.8%) 636/1059 (60.1%) 0.18**
Smoking (ever) 914/1610 (56.8%) 188/357 (52.7%) 184/309 (59.5%) 539/886 (60.8%) 0.04**
Arterial Hypertension 644/1644 (39.2%) 138/372 (37.1%) 129/322 (40.1%) 344/967 (35.6%) 0.25**
Diabetes 126/1644 (7.7%) 35/372 (9.4%) 25/322 (7.8%) 113/967 (11.7%) 0.005**
*analyzed with ANOVA
**analyzed with Chi2-test
doi:10.1371/journal.pone.0156778.t001
Table 2. Grading results.
AMD staging n
supercontrols 435
total no AMD 1673
unilateral early AMD 240
bilateral early AMD 139
total early AMD 379
unilateral intermediate AMD 132
bilateral intermediate AMD 201
total intermediate AMD 333
unilateral neovascular AMD 431
bilateral neovascular AMD 462
unilateral geographic atrophy 41
bilateral geographic atrophy 70
mixed type 55
total late AMD 989
total group 3444
AMD = age-related macular degeneration, late AMD, mixed type shows neovascular AMD in one eye and
geographic atrophy in the fellow-eye.
doi:10.1371/journal.pone.0156778.t002
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Discussion
While genetic risk factors for late AMD are well established, less is known for early stages of
the disease. In this study, we showed that genetic associations were stronger with increasing
disease severity. Genetic discrimination between AMD and controls was higher for late stages
of the disease and was also higher for bilateral compared to unilateral cases. For bilateral late
AMDmixed type the discrimination was almost perfect.
It has been previously shown that genetic factors differ between early and late AMD [7,8].
Our results support these findings in more detail and suggest that there is a disease continuum
from early to late AMD based on genetic factors.
Table 3. Distribution of single nucleotide polymorphisms rs10490924 in ARMS2 and rs1061170 in
CFH and trend test of AMD severity stages (data of other SNPs is shown in S1 Table).
AMD staging ARMS2 (rs10490924) CFH (rs1061170)
no AMD GG: 961 (57.9%) TT: 646 (39.0%)
GT: 606 (36.5%) TC: 796 (48.1%)
TT: 92 (5.5%) CC: 214 (12.9%)
unilateral early AMD GG: 119 (50.0%) TT: 88 (37.4%)
GT: 105 (44.1%) TC: 116 (49.4%)
TT: 14 (5.9%) CC: 31 (13.2%)
bilateral early AMD GG: 83 (60.6%) TT: 42 (22.0%)
GT: 43 (31.4%) TC: 69 (46.9%)
TT: 11 (8.0%) CC: 28 (20.1%)
unilateral intermediate AMD GG: 60 (45.5%) TT: 47 (35.6%)
GT: 56 (42.4%) TC: 58 (43.9%)
TT: 16 (12.1%) CC: 27 (20.5%)
bilateral intermediate AMD GG: 86 (43.2%) TT: 44 (22.0%)
GT: 85 (42.7%) TC: 91 (45.5%)
TT: 28 (14.1%) CC: 65 (32.5%)
unilateral neovascular AMD GG: 147 (34.6%) TT: 81 (19.1%)
GT: 180 (42.4%) TC: 196 (46.2%)
TT: 98 (23.1%) CC: 147 (34.7%)
bilateral neovascular AMD GG: 122 (26.8%) TT: 90 (19.8%)
GT: 210 (46.2%) TC: 204 (44.8%)
TT: 123 (27.0%) CC: 161 35.4%)
unilateral geographic atrophy GG: 16 (39.0%) TT: 7 (17.1%)
GT: 15 (36.6%) TC: 23 (56.1%)
TT: 10 (24.4%) CC: 11 (26.8%)
bilateral geographic atrophy GG: 21 (30.4%) TT: 7 (10.0%)
GT: 32 (46.4%) TC: 39 (55.7%)
TT: 16 (23.2%) CC: 24 (34.3%)
late AMD mixed type GG: 14 (25.5%) TT: 9 (16.4%)
GT: 26 (47.3%) TC: 23 (41.8%)
TT: 15 (27.3%) CC: 23 (41.8%)
trend test (p-value) <0.0001a / <0.0001b <0.0001c / <0.0001d
AMD = age related macular degeneration
a: GG + GT vs. TT
b: GG vs. GT + TT
c: TT + TC vs. CC
d: TT vs. TC + CC
doi:10.1371/journal.pone.0156778.t003
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We also found that only few loci were associated with early disease as opposed to late-stage
disease. These results are in line with other studies showing differences in heritability [9,11]
and effect size [10] between early and late AMD.
However, all AMD stages shared some risk variants. For example, risk variants in CFH and
ARMS2 conferred a risk from early to late stages of the disease. In addition, it is possible that
Table 4. Univariate regression analysis for each severity stage with results for SNPs rs10490924 in
ARMS2 and rs1061170 inCFH (data of other SNPs is shown in S2 Table).
AMD staging ARMS2 (rs10490924) CFH (rs1061170)
supercontrols 0.45, p = 0.03 0.65, p = 0.08
0.52, p = 0.09 0.66, p = 0.08
unilateral early AMD 1.47, p = 0.008 1.08, p = 0.61
1.34, p = 0.33 1.10, p = 0.68
bilateral early AMD 0.87, p = 0.49 1.40, p = 0.10
1.55, p = 0.20 2.17, p = 0.003
unilateral intermediate AMD 1.59, p = 0.02 1.03, p = 0.90
3.36, p = 9.44x10-5 1.80, p = 0.02
bilateral intermediate AMD 1.69, p = 0.002 1.70, p = 0.006
4.14, p = 1.68x10-8 4.85, p = 3.56x10-13
unilateral neovascular AMD 2.08, p = 1.21x10-8 2.04, p = 1.35x10-6
8.23, p = 1.00x10-13 5.97, p = 1.00x10-13
bilateral neovascular AMD 3.18, p = 1.01x10-13 2.07 p = 3.56x10-6
14.86, p = 1.00x10-13 6.86 p = 1.00x10-13
unilateral geographic atrophy 1.60, p = 0.21 2.88, p = 0.02
8.28, p = 1.60x10-6 5.52, p = 0.001
bilateral geographic atrophy 2.54, p = 0.001 4.76, p = 0.0002
9.64, p = 8.77x10-10 11.97, p = 3.53x10-8
late AMD mixed type 3.42, p = 0.001 2.40, p = 0.04
16.93, p = 5.21x10-11 9.93 p = 1.06x10-7
First line: heterozygous variant, second line: homozygous variant showing odds ratio and p-value. Analysis
adjusted for age, reference: no AMD; SNPs = single nucleotide polymorphisms, AMD = age-related
macular degeneration, interm. = intermediate, nAMD = neovascular AMD, GA = geographic atrophy.
doi:10.1371/journal.pone.0156778.t004
Table 5. Multivariate regression model for each severity stage with results for SNPs rs10490924 in
ARMS2 and rs1061170 inCFH (data of other SNPs is shown in S3 Table).
AMD staging ARMS2 (rs10490924) CFH (rs1061170)
unilateral early AMD 1.32 (1.02–1.72), p = 0.04 1.18 (0.86–1.63), p = 0.30
bilateral early AMD 1.08 (0.76–1.54), p = 0.68 1.20 (0.80–1.79), p = 0.38
unilateral intermediate AMD 1.97 (1.41–2.76), p = 7.91x10-5 1.28 (0.85–1.94), p = 0.23
bilateral intermediate AMD 2.83 (2.07–3.86), p = 6.06x10-6 1.39 (0.97–2.00), p = 0.08
unilateral neovascular AMD 3.01 (2.39–3.79), p = 6.24x10-21 1.80 (1.34–2.41), p = 9.36x10-5
bilateral neovascular AMD 4.76 (3.58–6.32), p = 6.49x10-27 1.75 (1.25–2.46), p = 6.06x10-6
unilateral geographic atrophy 4.86 (2.45–9.62), p = 5.98x10-6 1.50 (0.64–3.52), p = 0.36
bilateral geographic atrophy 3.36 (1.79–6.29), p = 0.0002 1.71 (0.78–3.72), p = 0.18
late AMD mixed type 4.27 (2.22–8.22), p = 1.36x10-5 2.45 (1.04–5.78), p = 0.04
Odds ratios and 95% Conﬁdence intervals are shown, reference: no AMD.
doi:10.1371/journal.pone.0156778.t005
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there are additional yet unknown unique risk variants driving the onset and the progression of
AMD. Despite of large genome-wide association studies, these factors have not yet been
detected. Therefore, other possibilities have to be taken into account. An explanation might be
that different variants produce synergistic effects for progression of the disease, but the identifi-
cation of those patterns would be very challenging. Another explanation could be a higher phe-
notypic and genetic heterogeneity of early AMD. Maybe, the time of onset of AMD is driven
by different pathways in different subjects. This would lower the effect sizes of a particular risk
variant on the population level despite similar effect sizes in individuals.
Additionally, there may be some forms of „early AMD”that do not progress to late AMD
although their clinical appearance can not yet be distinguished from other, progressing forms
of early AMD. On the other hand, studies on very old individuals indicate that the majority of
patients will eventually develop late AMD [15].
In this study, only CFH variants showed an effect in early AMD in univariate analyses. The
role of CFH in early AMD was also described in other reports [16,17]. In the ARED study, the
involvement of the complement system was discussed to be associated with early drusen for-
mation [18]. The effect of risk variants in other genes of the complement system such as C3
and CFB as well as other pathways became significant only in intermediate and late AMD. This
is also consistent with reports showing an involvement of these genes with late AMD [19,20].
Likewise, in our multivariate model, significant associations were only seen for the SNPs in CFH
(rs800292 and rs12144939), ARMS2 (rs10490924), and rs3764261 in the Cholesterylester transfer
gene [21–23]. This again highlights the importance of CFH and ARMS2 in all stages of AMD.
We also analyzed very subtle age-related changes in SDOCT images. We compared persons
without any retinal changes (“supercontrols”) with persons having minor abnormalities but
not yet being classified as AMD (“no AMD”). Both groups showed no significant genetic
Table 6. Area under the curve (AUC) of risk models in different AMD severity stages.
AMD staging AUC 95% CI p-value
unilateral early AMD 0.629 0.586–0.672 3.55x10-8
bilateral early AMD 0.669 0.611–0.727 2.85x10-8
unilateral intermediate AMD 0.789 0.747–0.831 1.70x10-22
bilateral intermediate AMD 0.831 0.792–0.870 1.45x10-36
unilateral neovascular AMD 0.835 0.805–0.865 9.86x10-66
bilateral neovascular AMD 0.917 0.896–0.937 8.93x10-104
unilateral geographic atrophy 0.902 0.826–0.979 3.70x10-11
bilateral geographic atrophy 0.933 0.893–0.974 7.15x10-19
late AMD mixed type 0.957 0.923–0.991 2.33x10-22
AMD = age-related macular degeneration, CI = conﬁdence interval
doi:10.1371/journal.pone.0156778.t006
Table 7. Univariate regression analysis for SNPs rs10490924 in ARMS2 and rs1061170 in CFH in
patients with unilateral nAMD and different severity stages of the fellow-eye.
Staging of fellow-eye ARMS2 (rs10490924) CFH (rs1061170)
No AMD 1.66 (1.19–2.32) p = 0.03 1.74 (1.27–2.39) p = 0.01
Early AMD 2.54 (1.87–3.46) p = 3.30x10-9 2.35 (1.73–3.19) p = 4.72x10-8
Intermediate AMD 3.45 (1.08–1.12) p = 4.00x10-29 3.01 (2.42–3.74) p = 2.82x10-23
Odds ratios and 95% conﬁdence intervals are shown, analysis adjusted for age. reference: no AMD;
SNP = single nucleotide polymorphism, AMD = age-related macular degeneration.
doi:10.1371/journal.pone.0156778.t007
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difference. This goes in line with the findings of Ferris at al, where small drusen were called
druplets to underline that they are normal aging changes without a higher risk for developing
AMD [24]. However, although not reaching significance risk variants showed lower OR in
supercontrols, which is suggestive that even these small changes are first signs of the disease
and are at least partially driven by common AMD risk variants.
In this study, we demonstrated that the phenotype of both eyes and not only the worst
affected may influence genetic susceptibility. We observed higher discrimination between cases
and controls and higher genetic associations with more severe involvement of the fellow-eye.
Previously published AMD prediction models include demographic, genetic and environmen-
tal factors for AMD, but the associations between phenotype and genotype are mostly based on
the more severely affected eye [25]. However, this conventional case-control approach of asso-
ciation testing does not provide all the information of the complex disease.
Our study has several limitations: the design as a case-control study has no follow-up and
therefore prediction models for AMD progression cannot be provided. Our results suggest an
increased genetic influence of known genetic factors on late AMD compared to early AMD,
but they are not able to explain the cause. Additionally, the effect of age on AMD development
is enormous and despite an adjustment for age in our calculations there might be a remaining
influence of age in our analysis. Further studies containing large numbers of cases with GA and
late AMDmixed type are needed to validate our results.
Strength of our study was the use of multimodal imaging for AMD staging combining fun-
dus photographs and SDOCT. This guaranteed a superior differentiation of phenotypes com-
pared to the majority of genetic studies.
In summary, genetic risk variants primarily established for late AMD showed reduced
effects on early stages of the disease. Associations of these variants with AMD became stronger
with increasing disease severity, which also led to an increasing discriminative ability. Our
results also underline the importance of the second eye in AMD patients because the genetic
predisposition was also associated with the disease severity of the fellow-eye. Future studies are
needed to identify the processes leading to the onset of early AMD and the progression to late
AMD in order to develop treatments to prevent vision loss.
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